Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. develops clinical-stage antiviral therapeutics based on its nanoviricide technology and host-mimetic nanomedicine approach. Company news centers on NV-387, its lead broad-spectrum antiviral candidate, including clinical development for MPox, respiratory viral infections, measles and other viral diseases, as well as manufacturing updates for clinical product forms such as NV-387 Oral Gummies.
Recurring updates also cover FDA orphan-drug designation activity, rare-disease regulatory strategy, investor-conference participation and the company’s relationship with TheraCour Pharma for antiviral drug development technology. The news flow is focused on antiviral pipeline progress, regulatory designations and disease-area positioning rather than commercial product sales.
NanoViricides (NYSE:NNVC) filed a Rare Pediatric Disease Drug (RPDD) designation application for NV-387 as a treatment for measles on April 7, 2026, to be considered alongside an earlier Orphan Drug application.
The company noted potential eligibility for a tradable Priority Review Voucher (PRV) worth roughly $160M if approved, and cited rising U.S. measles cases and pediatric incidence supporting the RPDD case.
NanoViricides (NYSE American:NNVC) announced a Phase II clinical trial of NV-387 for MPox will begin soon in the Democratic Republic of Congo following ACOREP approval. CRO site prep and staff training are scheduled in early April 2026, with enrollment and dosing to commence after training. The company has applied for US FDA Orphan Drug Designation and cites potential economic benefits and Strategic National Stockpile opportunities.
NanoViricides (AMEX:NNVC) announced on March 11, 2026 that it will present at NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, 2026, and that manufacture of the Phase II clinical drug product NV-387 Oral Gummies is complete.
The company says NV-387 completed a Phase I trial with no reported adverse events and has regulatory clearance from ACOREP in the Democratic Republic of Congo to enter a Phase II trial for Monkeypox (MPox). Management will be available for investor meetings at the conference.
NanoViricides (NYSE American: NNVC) filed an application on February 12, 2026 for Orphan Drug Designation with the US FDA OOPD for NV-387 as a treatment for MPox. The filing cites qualifying incidence (~2,042 cases in 2025) and seeks incentives including tax credits, user-fee exemptions, and potential seven years of market exclusivity if approved.
The company notes NV-387 completed a Phase I safety trial with no reported adverse events and showed efficacy in relevant animal models. NanoViricides engaged regulatory consultant Only Orphans Cote for the ODD submission.
NanoViricides (NYSE:NNVC) filed an application for Orphan Drug Designation (ODD) with the FDA for NV-387 as a treatment for measles on February 10, 2026. The company cites rising measles cases (2,251 cases in 2025; 727 cases as of Feb 5, 2026) and says NV-387 showed strong in vivo activity in a humanized animal model. If granted, ODD could provide tax credits, fee exemptions, and up to seven years of market exclusivity.
NanoViricides (NYSE American: NNVC) announced an interview with President Dr. Anil R. Diwan describing the company's nanoviricide technology and lead candidate NV-387. NV-387 completed Phase I with no reported adverse events and is positioned to begin a Phase II Mpox trial in the Democratic Republic of Congo with ACOREP permission.
Dr. Diwan highlighted broad-spectrum animal efficacy (Influenza, RSV, coronaviruses, MPox, smallpox, measles) including complete cure in RSV lethal models and superiority to existing influenza therapeutics in animal studies.
NanoViricides (NYSE:NNVC) highlighted the need for broad‑spectrum antivirals amid a moderately severe 2025–26 influenza season driven by an H3N2 K subclade. CDC estimates cited include 15,000,000 illnesses, 180,000 hospitalizations, and 7,400 deaths as of January 6, 2026. The company positions its Phase II candidate NV-387 as a broad‑spectrum antiviral that targets virus binding to heparan sulfate and is active in animal models versus influenza A/H3N2, RSV and coronaviruses. NV-387 is claimed superior to oseltamivir and baloxavir in animal studies and produced a complete cure in an RSV model. NanoViricides says NV-387 could address a >$20 billion market if approved and is planning a Phase II trial for empiric treatment of respiratory viral infections.
NanoViricides (NYSE:NNVC) signed a Master Services Agreement on December 1, 2025 with Only Orphans Cote to develop an orphan drug regulatory strategy and prosecute orphan designation applications for NV-387 at the US FDA.
NV-387 has shown in vivo activity in lethal mouse orthopoxvirus (ectromelia) models and in a humanized animal measles model, and the company is focused on advancing NV-387 toward Phase II human trials. The release cites potential orphan incentives including tax credits, user-fee exemptions, and seven years of market exclusivity if approved. As of November 25, 2025, the release reports 1,798 confirmed US measles cases across 42 states.
NanoViricides (NYSE Amer.: NNVC) filed its Form 10-Q for the quarter ended September 30, 2025 and reported clinical and financing updates for its lead candidate NV-387.
Key financials as of 9/30/2025: $1.25M cash, $8.36M total assets (including $6.78M net P&E), and $1.18M current liabilities. Net cash used in Q3 was $1.59M.
Subsequent financings raised ~$6.1M (cash added as of 11/12/2025), including a $5.5M registered direct/private placement on 11/10/2025, plus ATM proceeds and a $3M founder line of credit. Company states runway is not sufficient to fund operations through Feb 14, 2026 without additional financing.
NanoViricides (NYSE American:NNVC) will present at the Pharma Partnering Summit 2025 in Boston on November 14, 2025 at 11:25 AM ET. The presentation by Anil R. Diwan will update the company, its drug pipeline and licensing opportunities.
The release highlights lead candidate NV-387, now in Phase II development and reported effective in animal models against Influenza A/H3N2, RSV, coronaviruses, MPox/smallpox and measles, and positioned for respiratory ARI/SARI indications.